Key Takeaways
- Armstrong’s plans for a gene-editing company reflect advancements in safe DNA editing technology.
- Current laws in the US prohibit the creation of gene-edited babies, although public sentiment shows support for genetic modifications to treat diseases.
- No US company has actively pursued embryo editing due to legal and funding challenges, with research largely limited to academic institutions.
Shifting Perspectives on Gene-Edited Embryos
Recent comments from Armstrong suggest a potential shift in the gene-editing landscape in the US. His ambitions come after fluctuating perspectives in the field, particularly since 2018 when a controversial Chinese experiment resulted in genetically edited children, inciting global condemnation and criminal repercussions for its orchestrator.
Dieter Egli, a gene-editing expert at Columbia University, believes that advancements in technology like base editing—capable of altering single DNA letters without damaging the DNA helix—have made embryo editing a more feasible and safer pursuit. He asserts that scientists have a clearer understanding of how to manipulate DNA than in the past. “We know much better now what to do,” Egli explains, indicating a significant shift in the capacity to utilize these techniques in embryo research.
Embryo editing, aiming to produce genetically designed humans, remains a contentious issue. While research on embryos is permitted in the lab, creating gene-edited babies is illegal in most nations, including the US, where the Food and Drug Administration is barred from even reviewing applications for such endeavors. Nevertheless, if compelling evidence of the technology’s benefits can emerge, a change in regulations could be on the horizon, potentially spurred by investment from wealthy advocates.
In a post discussing these advancements, Armstrong referenced a 2017 Pew Research Center poll that revealed a majority of Americans were supportive of genetic alterations if they could alleviate diseases—yet the same poll indicated a significant opposition to embryo experiments. This dichotomy reflects the ongoing societal debates about the ethical implications of genetic editing.
To date, no US-based company has publicly explored the realm of embryo editing, largely due to stringent regulations and a lack of federal funding for such research. Instead, this area of study is being pursued by a couple of academic institutions: Egli’s lab at Columbia University and another at Oregon Health & Science University. These centers are pioneering research while navigating the complexities of legal constraints and public sentiment toward gene editing.
As technological advancements surge forward, the future of gene editing—particularly in terms of embryo alterations—may find itself increasingly at the intersection of innovation, ethics, and public policy.
The content above is a summary. For more details, see the source article.